Nutriband Inc (NTRB) - Net Assets

Latest as of January 2026: $6.68 Million USD

Based on the latest financial reports, Nutriband Inc (NTRB) has net assets worth $6.68 Million USD as of January 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.55 Million) and total liabilities ($868.45K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Nutriband Inc to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets $6.68 Million
% of Total Assets 88.49%
Annual Growth Rate N/A
5-Year Change -43.68%
10-Year Change 28804.27%
Growth Volatility 1295.76

Nutriband Inc - Net Assets Trend (2016–2026)

This chart illustrates how Nutriband Inc's net assets have evolved over time, based on quarterly financial data. See NTRB defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Nutriband Inc (2016–2026)

The table below shows the annual net assets of Nutriband Inc from 2016 to 2026. For live valuation and market cap data, see NTRB company net worth.

Year Net Assets Change
2026-01-31 $6.68 Million +3.90%
2025-01-31 $6.43 Million -0.14%
2024-01-31 $6.44 Million -24.90%
2023-01-31 $8.57 Million -27.71%
2022-01-31 $11.86 Million +66.75%
2021-01-31 $7.11 Million +3953.94%
2020-01-31 $175.43K -92.70%
2019-01-31 $2.40 Million +1878.97%
2018-01-31 $121.51K +425.80%
2017-01-31 $23.11K +301.47%
2016-01-31 $-11.47K --

Equity Component Analysis

This analysis shows how different components contribute to Nutriband Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 4666606400.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (January 2026)

Component Amount Percentage
Common Stock $12.16K 0.18%
Other Comprehensive Income $-304.00 0.00%
Other Components $53.36 Million 798.86%
Total Equity $6.68 Million 100.00%

Nutriband Inc Competitors by Market Cap

The table below lists competitors of Nutriband Inc ranked by their market capitalization.

Company Market Cap
Alpha Exploration Ltd
V:ALEX
$37.20 Million
Virtualware 2007 S.A.
PA:MLVIR
$37.22 Million
Greenland Mines Ltd
NASDAQ:GRML
$37.22 Million
5TH PLANET GAMES DK -50
F:2HG1
$37.22 Million
Shanghai Guijiu Co Ltd
SHG:600696
$37.20 Million
Profoto Holding AB
ST:PRFO
$37.19 Million
Panjawattana Plastic Public Company Limited
BK:PJW
$37.19 Million
WHA Business Complex Freehold and Leasehold Real Estate Investment Trust
BK:WHABT
$37.15 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Nutriband Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2025 to 2026, total equity changed from 6,429,000 to 6,679,488, a change of 250,488 (3.9%).
  • Net loss of 8,229,632 reduced equity.
  • New share issuances of 5,305,503 increased equity.
  • Other factors increased equity by 3,174,617.

Equity Change Factors (2025 to 2026)

Factor Impact Contribution
Net Income $-8.23 Million -123.21%
Share Issuances $5.31 Million +79.43%
Other Changes $3.17 Million +47.53%
Total Change $- 3.90%

Book Value vs Market Value Analysis

This analysis compares Nutriband Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 5.33x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-01-31 $0.00 $3.06 x
2017-01-31 $0.00 $3.06 x
2018-01-31 $0.02 $3.06 x
2019-01-31 $0.39 $3.06 x
2020-01-31 $0.03 $3.06 x
2021-01-31 $1.06 $3.06 x
2022-01-31 $1.49 $3.06 x
2023-01-31 $1.01 $3.06 x
2024-01-31 $0.81 $3.06 x
2025-01-31 $0.61 $3.06 x
2026-01-31 $0.57 $3.06 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Nutriband Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -123.21%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -404.08%
  • • Asset Turnover: 0.27x
  • • Equity Multiplier: 1.13x
  • Recent ROE (-123.21%) is above the historical average (-466.28%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 0.00% 0.00% 0.00x 0.00x $747.00
2017 -654.55% 0.00% 0.00x 1.63x $-153.57K
2018 -2198.99% 0.00% 0.00x 1.36x $-2.68 Million
2019 -138.54% -1358.11% 0.09x 1.17x $-3.57 Million
2020 -1593.22% -754.10% 0.17x 12.53x $-2.81 Million
2021 -45.18% -340.52% 0.10x 1.40x $-3.92 Million
2022 -71.02% -592.23% 0.11x 1.07x $-9.61 Million
2023 -56.12% -231.33% 0.22x 1.10x $-5.67 Million
2024 -85.20% -263.04% 0.28x 1.17x $-6.13 Million
2025 -163.06% -489.86% 0.29x 1.16x $-11.13 Million
2026 -123.21% -404.08% 0.27x 1.13x $-8.90 Million

Industry Comparison

This section compares Nutriband Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $155,285,360
  • Average return on equity (ROE) among peers: -101.11%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Nutriband Inc (NTRB) $6.68 Million 0.00% 0.13x $37.20 Million
Aardvark Therapeutics, Inc. Common Stock (AARD) $-34.80 Million 0.00% 0.00x $83.17 Million
Abcellera Biologics Inc (ABCL) $830.51 Million 14.32% 0.21x $1.61 Billion
Abeona Therapeutics Inc (ABEO) $-26.99 Million 0.00% 0.00x $321.39 Million
Acumen Pharmaceuticals Inc (ABOS) $266.97 Million -19.62% 0.16x $155.29 Million
Abpro Holdings, Inc. (ABP) $3.07 Million -479.81% 1.57x $2.00 Million
Absci Corp (ABSI) $179.13 Million -57.56% 0.19x $1.01 Billion
Arbutus Biopharma Corp (ABUS) $182.50 Million -46.25% 0.30x $831.63 Million
ABVC Biopharma Inc (ABVC) $4.59 Million -357.76% 1.38x $35.10 Million
Abivax SA American Depositary Shares (ABVX) $33.94 Million -14.97% 0.12x $7.98 Billion
ACADIA Pharmaceuticals Inc (ACAD) $113.93 Million -49.49% 0.18x $3.66 Billion

About Nutriband Inc

NASDAQ:NTRB USA Biotechnology
Market Cap
$37.20 Million
Market Cap Rank
#23061 Global
#4974 in USA
Share Price
$3.06
Change (1 day)
-7.55%
52-Week Range
$3.06 - $10.72
All Time High
$43.54
About

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA b… Read more